Compare FTK & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | ORIC |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.7M | 861.3M |
| IPO Year | 1997 | 2020 |
| Metric | FTK | ORIC |
|---|---|---|
| Price | $24.11 | $7.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $20.00 | $19.73 |
| AVG Volume (30 Days) | 323.4K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | 19.67 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $196.25 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $10.96 | $7.23 |
| 52 Week High | $25.54 | $14.93 |
| Indicator | FTK | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 41.43 |
| Support Level | $15.01 | $7.68 |
| Resistance Level | N/A | $9.13 |
| Average True Range (ATR) | 1.54 | 0.52 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 76.71 | 27.84 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.